CJC-1295 Guide: Research Benefits & Quality Standards

A single unverified certificate of analysis can quietly compromise months of laboratory research before reconstitution even begins. When sourcing synthetic growth hormone secretagogues like CJC-1295, investigators routinely face catalog nomenclature errors, unverified purity claims, and batch-to-batch degradation that directly skew in-vitro findings. Precision demands proof. You shouldn’t have to risk assay reproducibility or waste laboratory resources on vendor self-certification and ambiguous chemical profiles.

This guide delivers a systematic, evidence-based breakdown of CJC-1295, detailing its molecular architecture, somatotroph receptor kinetics, and analytical testing standards. We clarify the exact chemical distinctions between CJC-1295 with DAC and Modified GRF 1-29, establish essential purity thresholds, and outline the chromatographic criteria necessary to confirm authentic research compounds. Below, we examine the structural mechanics of this tetrasubstituted analog and establish the procedural benchmarks required for reliable laboratory procurement.

What Is CJC-1295? Chemical Structure and Molecular Characterization

CJC-1295 is a synthetic 29-amino-acid tetrasubstituted peptide analog engineered to function as a selective growth hormone-releasing hormone (GHRH) receptor agonist. Synthesized strictly for in-vitro evaluation and laboratory research, this compound activates somatotroph signaling pathways without inducing cellular toxicity under controlled experimental conditions. Native human GHRH(1-29) undergoes rapid proteolysis within minutes in biological fluids. To overcome this limitation, CJC-1295 incorporates four specific amino acid substitutions that resist enzymatic cleavage while preserving full receptor binding affinity.

To examine the physiological pathways and research context surrounding this growth hormone secretagogue, watch this technical breakdown:

Tetrasubstituted GHRH Analog vs. Native Peptide

In native GHRH sequences, dipeptidyl peptidase-4 (DPP-4) targets the N-terminal Ala2 residue, rapidly rendering the molecule biologically inactive. Synthetic modification replaces this vulnerable site. The specific substitutions include:

• D-Ala2: Prevents N-terminal scission by DPP-4 proteases.
• Gln8: Reduces spontaneous deamidation during storage and testing.
• Ala15: Preserves bioactivity while enhancing structural stability.
• Leu27: Prevents methionine oxidation that disrupts receptor interaction.

Unconjugated Mod GRF 1-29 carries the empirical formula C₁₅₂H₂₅₂N₄₄O₄₂ and a theoretical molecular weight of 3,367.9 Da. Structural stability is significantly higher than wild-type fragments.

CJC-1295 DAC vs. CJC-1295 No DAC (Mod GRF 1-29)

Catalog confusion frequently clouds peptide procurement. The defining structural difference lies in the Drug Affinity Complex (DAC). CJC-1295 with DAC incorporates a Lys30 residue linked to maleimidopropionic acid (MPA), yielding the formula C₁₆₅H₂₆₉N₄₇O₄₆ with a molecular mass of 3,647.2 Da (CAS 863288-34-0).

The electrophilic maleimide group forms a covalent thioether link with the free thiol on cysteine-34 of serum albumin. In assays containing albumin, this bioconjugation extends functional stability from roughly 30 minutes to several days. Assays lacking albumin or requiring short pulsatile signaling demand unconjugated Mod GRF 1-29 instead. Researchers must select variants based strictly on cellular media composition and planned assay duration.

In Vitro Pharmacodynamics and Receptor Kinetics

Selective activation of the Growth Hormone-Releasing Hormone Receptor (GHRH-R) initiates a distinct intracellular signaling cascade. When CJC-1295 engages the extracellular binding domain of this G-protein coupled receptor, it triggers the exchange of GDP for GTP on the Gαs subunit. This dissociation activates membrane-bound adenylate cyclase. Intracellular adenosine triphosphate (ATP) rapidly converts to cyclic adenosine monophosphate (cAMP), driving the primary downstream endocrine response. Elevated cAMP binds the regulatory subunits of protein kinase A (PKA), releasing catalytic subunits that translocate to the nucleus.

PKA then phosphorylates the cAMP response element-binding protein (CREB). This phosphorylation stimulates transcription of the growth hormone gene while simultaneously opening L-type voltage-gated calcium channels. Pituitary cell models demonstrate that this dual pathway, cAMP generation coupled with rapid intracellular calcium influx, governs hormone vesicle exocytosis. Structural details and chemical identifiers for confirming compound identity prior to assay design are available in the PubChem compound profile for CJC-1295.

GHRH Receptor Selectivity and Intracellular Cascades

Competitive binding assays show high target specificity. CJC-1295 exhibits sub-nanomolar affinity for the pituitary GHRH receptor, displacing native ligands effectively. Crucially, in-vitro profiling confirms no off-target affinity across adjacent pituitary receptors:

• Zero cross-reactivity: Assays detect no cross-activation at somatostatin receptors (SSTR1-5).
• Selectivity over corticotropin: The compound produces no signal transduction across CRH or ACTH pathways.
• Thyrotropic isolation: TRH and TSH cascades show zero induction during exposure.
• Prolactin preservation: Dopamine D2 receptor systems remain completely unaffected.

Comparative Half-Life and Biostability Profiles

Receptor exposure profiles diverge sharply between modified variants. Unconjugated Mod GRF 1-29 delivers a short, pulsatile signaling window. It exhibits an in-vitro media half-life of roughly 30 minutes due to standard serum proteolysis. Conversely, CJC-1295 with DAC creates continuous receptor occupancy. Its stable bioconjugation to endogenous albumin shields susceptible peptide bonds from cleavage, extending in-vitro functional stability beyond 6 to 8 days.

Thermal degradation assays demonstrate that unprotected fragments undergo secondary structure breakdown when incubated at 37°C for more than 4 hours. Albumin-conjugated variants retain functional tertiary architecture under identical thermal stress. To verify that analytical supplies adhere to verified stability standards before running kinetic experiments, review the baseline criteria detailed in our Scientific Research Chemical Supply Guide, or examine verified research compounds tested specifically for in-vitro assay consistency.

Laboratory Reconstitution and Handling Protocols for In-Vitro Assays

Maintaining the structural integrity of synthetic peptides during wet-lab execution requires strict environmental control. Reconstitution procedures for CJC-1295 must occur inside a certified Class II, Type A2 laminar flow biosafety cabinet to prevent airborne microbial contamination. Solvent selection directly governs solubilization efficiency. High-purity bacteriostatic water (containing 0.9% benzyl alcohol) or analytical-grade sterile saline (0.9% NaCl) serves as the primary diluent for in-vitro assay preparation. Standard sterile water for injection (SWFI) remains acceptable solely for immediate-use protocols lacking antimicrobial preservation requirements.

Temperature regulation dictates long-term peptide survival. Lyophilized cakes demonstrate superior structural stability when held at -20°C in a light-shielded, desiccated storage chamber. Reconstituted aqueous solutions, however, are highly susceptible to hydrolytic cleavage and deamidation, requiring maintenance strictly between 2°C and 8°C. Mechanical agitation presents an equal risk. Vortexing generates violent fluid shear stresses that disrupt tertiary peptide architecture, precipitating irreversible aggregate formation. Gentle, passive dissolution protects secondary bonding networks.

Step-by-Step Reconstitution Guidelines

Analytical consistency depends on reproducible dissolution mechanics. Researchers must execute the following sequential handling protocol:

• Step 1 (Thermal equilibration): Allow sealed lyophilized vials to equilibrate at ambient room temperature (20°C to 25°C) for 30 minutes before de-crimping. This eliminates internal condensation upon stopper removal.
• Step 2 (Controlled introduction): Aspirate the exact diluent volume using a low-retention pipette or fine-gauge needle. Direct the liquid stream down the interior glass wall, avoiding direct projection onto the lyophilized cake.
• Step 3 (Passive dissolution): Allow the diluent to permeate the peptide matrix spontaneously. Swirl the vial with slow, circular motions for 60 seconds; never vortex or shake the container.
• Step 4 (Visual confirmation): Examine the reconstituted solution against a polarized light source to verify total clarity, confirming the absence of undissolved particulates, cloudiness, or gelatinous fibrils.

Solvent Compatibility and Aliquot Storage

Repeated freezing and thawing rapidly destroys synthetic peptides. Ice crystal propagation shears peptide chains, causing significant potency loss after just two cycles. Upon achieving complete dissolution, partition the stock solution into single-use polypropylene low-binding cryovials.

Lyophilized CJC-1295 cakes remain stable at -20°C for up to 24 months when protected from light and moisture. Once reconstituted in bacteriostatic water and held at 2°C to 8°C, the solution maintains analytical stability for 14 to 30 days before measurable hydrolysis occurs. Solutions prepared in non-preserved analytical saline must be utilized within 24 to 48 hours to preserve assay reproducibility.

Analytical Verification Standards: HPLC and Mass Spectrometry for CJC-1295

Analytical precision requires rigorous multi-method verification. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) serves as the primary benchmark for quantifying peptide chemical purity. It separates target analytes from closely eluting synthesis impurities based on hydrophobic interactions with a stationary phase (typically C18 silica). However, chromatography alone cannot prove identity. Electrospray Ionization Mass Spectrometry (ESI-MS) provides the necessary confirmation by measuring the exact mass-to-charge (m/z) ratios of intact molecular ions. Pair these techniques to eliminate false positives.

Relying solely on vendor claims invites experimental error. The table below outlines how these orthogonal techniques cross-validate physical lots of CJC-1295:

Analytical Method	Primary Metric Measured	Expected CJC-1295 Profile	Critical Failure Indicator
RP-HPLC	Retention time (tr) & peak area under curve (AUC)	Sharp, symmetrical single peak; AUC ≥ 99.0%	Fronting, peak splitting, or baseline secondary shoulders
ESI-MS	Monoisotopic / average intact molecular mass	3,647.2 Da (with DAC) / 3,367.9 Da (No DAC)	Mass shifts matching deletion peptides (Δm/z ± 57 to 186 Da)

To inspect raw analytical chromatograms and learn how to audit analytical paperwork properly, consult our technical framework on How to Buy Research Chemicals with COA Documentation.

Deconstructing a Batch-Specific Certificate of Analysis (COA)

A legitimate Certificate of Analysis provides clear, unedited instrument outputs. Purity claims exceeding 99.0% must show full baseline separation on the chromatogram with integral tables reporting total peak areas. Audit the documentation to ensure the batch number printed on the physical vial crimp matches the report header exactly.

Independent third-party analytical laboratories provide vital objectivity. In-house vendor declarations frequently hide co-eluting peaks or smooth baseline noise. Genuine third-party validation provides direct traceability to analytical testing facilities.

Detecting Synthesis Impurities and Degradation Products

Solid-phase peptide synthesis (SPPS) inherently produces micro-impurities. Incomplete amino acid coupling yields truncated chains, while unblocked reactive sites create internal deletion sequences. These structurally similar artifacts can competitively inhibit GHRH receptors without initiating signal cascades.

Liquid chromatography also detects post-synthesis degradation. Storage failures cause deamidation at sensitive asparagine or glutamine sites, shifting retention times. Research protocols demand a baseline purity threshold of ≥ 99.0% by HPLC. For fully validated testing standards and verifiable chromatography, explore our third-party verified research compounds before initiating your next assay series.

Procuring Verified CJC-1295 for Laboratory Research in 2026

Procuring synthetic research materials for analytical and in-vitro testing requires rigorous vendor auditing. Institutional facilities, private laboratories, and university researchers must ensure physical lots match catalog chemical specifications precisely before issuing purchase orders. Unregulated grey-market sourcing exposes research facilities to mislabeled peptide sequences, truncated synthesis artifacts, and invalid test data. Every batch of CJC-1295 must be accompanied by comprehensive analytical proof that confirms both molecular identity and chromatographic purity.

Federal regulatory boundaries remain strictly defined. CJC-1295 is not approved for therapeutic use, human consumption, or clinical administration. Sourcing channels must operate within strict research boundaries, providing compounds designated exclusively for in-vitro and laboratory evaluation. For an exhaustive breakdown of institutional vendor auditing standards, consult our guide on Sourcing High Purity Research Peptides.

Vendor Evaluation Checklist for Research Laboratories

Procurement teams should apply clear operational criteria to screen potential chemical providers:

• Downloadable, batch-matched documentation: Ensure access to lot-specific HPLC and mass spectrometry reports before completing acquisitions. Generic catalog purity statements are unacceptable.
• Strict research demarcation: Confirm the supplier specializes exclusively in non-clinical, analytical, and in-vitro research grade materials, with no consumer health or supplement claims.
• Multi-vial procurement tiers: Verify secure digital checkout infrastructures that support structured bulk discount packages for large-scale experimental designs.
• Technical responsiveness: Test vendor support channels to confirm scientific personnel can resolve complex lot queries and provide raw analytical chromatograms upon request.

Domestic Supply Chain Integrity and Transit Protection

Domestic U.S. fulfillment remains critical for protecting peptide stability. International consignments routinely face severe clearance bottlenecks and prolonged exposure to uncontrolled ambient temperatures in non-conditioned transit hubs. These transit delays initiate hydrolytic degradation long before vials arrive at the receiving dock.

Domestic logistics bypass these risks entirely. Utilizing domestic distribution channels ensures consistent thermal management and rapid transit across national laboratories. Automated parcel monitoring provides end-to-end visibility from dispatch to intake. To assess the operational risk profiles of cross-border versus local fulfillment, review our comprehensive USA Based Research Compounds Supplier Sourcing Guide. Through batch-specific analytical verification, transparent third-party testing, and reliable domestic fulfillment with free shipping on orders over $200, JM Precision Labs serves as a trusted partner for authenticated research peptides across the United States.

Advancing Laboratory Standards in CJC-1295 Research

Rigorous in-vitro experimentation depends entirely on molecular fidelity. Differentiating between CJC-1295 with DAC and unconjugated Mod GRF 1-29 protects your assay design from mismatched kinetics. Implementing disciplined reconstitution protocols shields sensitive peptide sequences from hydrolytic shearing. Validating lot-matched chromatographic purity and mass spectrometry spectra ensures your published findings reflect authentic receptor dynamics rather than synthesis artifacts.

Eliminate supplier ambiguity. At JM Precision Labs, every batch undergoes independent third-party HPLC and mass spectrometry testing to verify theoretical mass and chromatographic integrity. Our analytical-grade compounds are restricted strictly to in-vitro and laboratory research applications. With rapid domestic U.S. shipping, real-time tracking, and structured bulk discount packages, your facility gains the supply chain security necessary for reproducible science.

Source Batch-Verified CJC-1295 for Laboratory Research and equip your facility with fully documented analytical compounds today.

Frequently Asked Questions

What is the structural difference between CJC-1295 DAC and Mod GRF 1-29?

The primary structural divergence is the Drug Affinity Complex (DAC) attached at the C-terminus. CJC-1295 with DAC is a 30-amino-acid peptide incorporating a maleimidopropionic acid linker conjugated to Lys30, enabling spontaneous covalent binding to serum albumin. In contrast, Mod GRF 1-29 is a 29-amino-acid tetrasubstituted fragment lacking this bioconjugation linker. This chemical difference alters in-vitro half-life from 30 minutes to multiple days in albumin-rich media.

Is CJC-1295 approved for human consumption or clinical therapy?

No, CJC-1295 is not approved by the FDA for clinical therapy, human consumption, or medical treatment. Regulatory bodies classify it strictly as an investigational research compound restricted to analytical and in-vitro laboratory experimentation. It is also prohibited in athletic competition under Section S2 of the World Anti-Doping Agency Prohibited List. Legitimate procurement channels distribute this peptide exclusively for controlled laboratory assay development.

How should reconstituted CJC-1295 peptide solutions be stored in a laboratory?

Reconstituted solutions require immediate refrigeration between 2°C and 8°C inside light-shielded, airtight containers. When dissolved in bacteriostatic water containing 0.9% benzyl alcohol, the aqueous solution remains analytically viable for 14 to 30 days. Reconstitution in preservative-free analytical saline reduces functional stability to 24 to 48 hours. Store the compound away from refrigeration fans and door seals to prevent mechanical vibration and localized temperature swings.

What analytical methods are required to verify the purity of CJC-1295?

Verifying compound quality requires a dual approach using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) alongside Liquid Chromatography-Mass Spectrometry (LC-MS). RP-HPLC quantifies chemical purity by measuring retention time and peak area integration, establishing whether the main analyte meets the ≥ 99.0% purity threshold. LC-MS calculates exact mass-to-charge ratios to confirm theoretical molecular weight, proving identity and identifying truncated synthesis deletion sequences.

Can CJC-1295 be dissolved directly in bacteriostatic water without cosolvents?

Yes, high-purity lyophilized cakes dissolve readily in sterile bacteriostatic water or analytical-grade physiological saline without requiring acetic acid or cosolvents. The hydrophilic amino acid profile of the tetrasubstituted chain allows rapid solubilization under neutral physiological pH. If optical haziness or insoluble particulates persist after gentle swirling, it indicates truncated peptide impurities, counter-ion imbalance, or severe mechanical aggregation rather than a standard solubility limitation.

What happens if a peptide solution experiences repeated freeze-thaw cycles?

Repeated thermal cycling rapidly destroys peptide integrity through physical and chemical denaturation. Ice crystal propagation creates intense micro-environmental mechanical stress, shearing peptide backbones and forcing secondary structure collapse. In addition, freeze-thaw cycles accelerate deamidation and peptide cleavage, resulting in significant loss of receptor potency. Investigators should divide reconstituted stock solutions into single-use polypropylene cryovials immediately following dissolution to prevent freeze-thaw degradation entirely.

Why is batch-specific COA verification critical when procuring CJC-1295 online?

Lot-matched verification ensures the exact physical vial delivered matches validated analytical specifications. Generic or recycled Certificates of Analysis frequently obscure batch-to-batch variation, residual synthesis solvents, and incomplete peptide sequences that distort in-vitro assay kinetics. Independent testing documentation confirms precise molecular mass and baseline purity exceeding 99.0%. Sourcing batch-verified research compounds from domestic suppliers like JM Precision Labs safeguards experimental reproducibility across every trial phase.